Full info forABBVIE
| Application ID | 1-1766-21421 |
| Status | IE Pass |
| Prioritization Number | 1632 |
| TLD (#13) | ABBVIE |
| IDN Translation (#14b) | -- |
| Applicant (#1) | Abbott Laboratories |
| Website (#5) | http://www.abbott.com |
| Application Type | |
| Type | Standard |
| Contested | no |
| Contested Numbers | 1 |
| GAC Early Warning | no |
| Cultural, Linguistic or Religious | no |
| dotBrand | yes |
| Trademark Class A | class 5 (pharma, dietetic food) |
| Trademark Class B | |
| Trademark Class C | |
| Industry Keyword | healthcare |
| Remark | Abbott has announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The research-based pharmaceutical company will include Abbottʹs current portfolio of proprietary pharmaceuticals and biologics, and will be named AbbVie. Both companies will be global leaders in their respective industries. Abbott will be applying for the .ABBVIE gTLD with the intended future mission and purpose of providing a trusted, hierarchical, and intuitive namespace for AbbVie products, services, and information. |
| Availability Data | |
| Sunrise Period: | fromunknown tounknown |
| Landrush Period: | fromunknown tounknown |
| GoLive: | unknown |
| Registration Policy | |
| Restricted | yes |
| Restrictions | dotbrand |
| Backend Provider | Afilias |
| Registry Website | |
| Keyword | |
| Keyword | no |
| English Meaning | -- |
| Appeal Ranking | 0 |
| Appeal Remark | Reserved for company and affiliate use only. |
| English | not applicable |
| Spanish | not applicable |
| Portuguese | not applicable |
| French | not applicable |
| Italian | not applicable |
| German | not applicable |
| Dutch | not applicable |
| Swedish | not applicable |
| Danish | not applicable |
| Mandarin | not applicable |
| Russian | not applicable |
| Location | |
| Region | North America |
| Country | United States |
| Community (#19) | -- |
| Geographic (#21a) | -- |
| Geographic Category | -- |
| IDN | |
| IDN (#14) | No |
| A-label (#14a) | -- |
| Translation (#14b) | -- |
| Script Code (#14d) | -- |
| Allows ASCII | yes |
| Applicant | |
| Applicant (#1) | Abbott Laboratories |
| Website (#5) | http://www.abbott.com |
| Applicant Address (#2) | 100 Abbott Park Road Abbott Park Illinois 60064 United States [US] |
| Applicant Phone (#3) | +1 847 937 6100 |
| Applicant Fax (#4) | +1 847 937 3675 |
| Legal Form (#8) | Corporation |
| Exchange Symbol (#9a) | New_York_Stock_Exchange |
| Parent Company (#9b) | |
| Joint Venture Partners (#9c) | |
| Primary Contact | |
| Name (#6) | Philip Lodico |
| Title (#6) | Managing Partner |
| e-mail (#6) | lodico.av@fairwindspartners.com |
| Secondary Contact | |
| Name (#7) | Dirk Hoerter |
| Title (#7) | Director, Digital Marketing Excellence |
| e-mail (#7) | dirk.hoerter@abbott.com |
| Mission / Purpose (#18a) | |
| 18.1 Mission and Purpose of .ABBVIE Abbott Laboratories (“Abbott”) is a global, diversified healthcare company devoted to the discovery, development, manufacture, and marketing of pharmaceuticals, nutritional products, and medical products including devices, diagnostic tests, and instruments. Abbott has sales, manufacturing, research and development, and distribution facilities around the world and is well-recognized for its global reach. Abbott employs over 90,000 people and has an online presence in over 75 countries. Its online content is accessible in the .COM gTLD and also in multiple ccTLDs. A sample of the ccTLDs in which Abbott posts content is as follows: .COM.AR, .COM.AU, .COM.CN, .DK, .FR, .DE, .CO.IN, .IE, JP, .NO, .ES, .CO.UK, .CA, and .US. On October 19, 2011, Abbott announced that it plans to separate into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. The research-based pharmaceutical company will include Abbottʹs current portfolio of proprietary pharmaceuticals and biologics, and will be named AbbVie. Both companies will be global leaders in their respective industries. Abbott will be applying for the .ABBVIE gTLD with the intended future mission and purpose of providing a trusted, hierarchical, and intuitive namespace for AbbVie products, services, and information. For more information, see the recent press release http:⁄⁄www.abbott.com⁄news-media⁄press-releases⁄2011-oct19-2.htm. As a diversified healthcare company, Abbott Laboratories currently manufactures and distributes numerous products around the world. AbbVie’s future portfolio of products will include proprietary pharmaceuticals and related goods and services. For more information, see: http:⁄⁄www.abbottinvestor.com⁄. As mentioned above, the intended future mission and purpose of the .ABBVIE gTLD is to serve as a trusted, hierarchical, and intuitive namespace for consumers of AbbVie’s products and services. Since AbbVie has not yet been legally formed at the time of filing this application, Abbott Laboratories is the designated entity to file this application and bring the .ABBVIE gTLD to market. Abbott is committed to moving forward with the .ABBVIE gTLD application. However, at the time of filing there is not enough information available to fully analyze and evaluate all potential use case options. Abbott anticipates a limited use of the .ABBVIE gTLD initially, with the possibility of expanding as market information becomes available and AbbVie’s digital strategy develops. Abbott and AbbVie, respectively, will be analyzing and evaluating other .BRAND gTLD applications, as well as general market adoption, to determine short- and long-term potential best-in-class use case options to more effectively serve and enhance AbbVie’s future online strategy as a leading research-based pharmaceutical company. The potential use of the .ABBVIE gTLD by AbbVie and its various business segments will also be driven by AbbVie’s future business strategies. Utilizing current projections based upon Abbott’s existing proprietary pharmaceuticals business, AbbVie’s potential business plans, and other strategic factors, Abbott estimates that second-level domain name registrations will be in line with the projections set forth in the financial template provided in response to Question 46 of this application. |
|
If you wish to download the application information pertaining to this new gTLD, please select your download preference below: 1) A PDF compilation of the information provided by eBrand Services will be generated for you.; 2) The public portion of the application made available by ICANN will be generated.
Be informed about the status of applicationABBVIE
Do you want to be kept up to date with the application status for a domain under a new gTLD?
We understand that the roll out of the new gTLD’s is a long process and you may be undecided on the specific domain you wish to pursue. Nonetheless, if you would like to be informed about the progress of a particular new gTLD, and all essential elements (policies, pricing, launch schedules, and registration deadlines), request a follow up and join our watchlist. Alternatively, let us review your business/situation and supply you with a customized solution fitting your individual needs.
File an objection for applicationABBVIE
eBrand Services has designed a series of defensive approaches to ensure that rightholders can object applications of new gTLD that affect their interests asserting prior rights over certain string or Trademark. Contact us to know more:
Express your interest for a domain name under the extensionABBVIE
An Expression of Interest allows you to submit a non-binding interest in registering the specific domains most relevant to you. By doing so, we can provide you with up-to-date information about launch schedules, pricing, policies, and ensure you avoid missing registration deadlines. Prior to the release of your domain name under a new gTLD, we will let you know and we can assist you in turning your Expression of Interest into a binding registration order, or cancel your Expression of Interest. Whilst we will endeavor to secure your desired domain for you, please note that we cannot guarantee a successful registration. It is important to acknowledge that multiple registration phases will take place. For more information, please refer our FAQ’s. All Expression of Interest’s are free of charge and legally non-binding.
Additionally, let us review your business/situation and supply you with a customized solution fitting your individual needs.
Contact us to know more: